DENVER, Colo. (247marketnews.com) -- Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.
Silexion Therapeutics (NASDAQ:SLXN) is grabbing immediate attention after unveiling new preclinical data for SIL204. The company reported that its RNAi candidate can harness naturally occurring circulating lipoproteins to enter KRAS-driven cancer cells and produce dose-dependent knockdown of mutant KRAS expression without synthetic nanoparticles or transfection reagents. Serum-lipid depletion significantly reduced gene-silencing efficiency, while adding extra LDL did not improve potency, findings Silexion says support the idea that normal physiological lipoprotein levels may already be sufficient for cellular uptake. SLXN is among the most actively traded stocks today.
The bigger story is what Silexion believes the mechanism could mean for systemic delivery. Chief Scientific and Development Officer Mitchell Shirvan called the findings “an essential mechanistic milestone,” while CEO Ilan Hadar said the results provide “a strong mechanistic foundation for systemic subcutaneous delivery.” The company is advancing SIL204 through a Phase 2/3 program in locally advanced pancreatic cancer while continuing pharmacokinetic, cellular-uptake and biodistribution studies.
Kraig Biocraft Laboratories’ (OTCQB:KBLB) headline is commercialization. Kraig announced shipment of its first commercial order of recombinant spider-silk yarn to a performance sports brand, putting its engineered fiber into a real-world customer development program. The shipment follows a year of manufacturing expansion, including a nearly 2.5-metric-ton cocoon production cycle and, most recently, completion of the foundational Atlas Gene Library under Project Atlas. The company says Atlas is designed to enable new spider-silk variants with customized strength, toughness and flexibility characteristics.
Kraig CEO Kim Thompson has described the customer shipment as “a huge milestone for Kraig Labs,” while emphasizing performance sports as a proving ground for the material. The potential market extends well beyond apparel, from protective equipment and technical textiles to aerospace, automotive and medical applications. For now, the important transition is from laboratory achievement to customer testing. If performance brands validate the fiber in finished products, Kraig could have a substantially different commercial story on its hands.
10x Genomics (NASDAQ:TXG) is moving its Atera spatial-biology platform from launch hype into commercial reality. The company has begun global shipments after reporting that booked orders had already exceeded the 40 instruments it expected to ship during 2026. 10x says nearly all of the world's top 20 R&D-spending biopharma companies are purchasing Atera systems or services, while projects have been booked across more than 100 customers. CEO Serge Saxonov said, “Today is just the beginning,” as the company positions Atera as a platform for large-scale spatial biology, translational research and AI-oriented biological datasets.
The Atera launch also gives TXG another potential growth lever after a period in which the company has been working to expand its spatial-biology franchise. Early research programs span oncology, neuroscience, immunology and other disease areas, while institutions including the Allen Institute and Wellcome Sanger Institute are preparing large-scale projects. The company has also outlined future capabilities involving slide-preparation automation, RNA-protein multiomics and mutation detection. With Atera now shipping, the market gets its first meaningful test of whether the platform's early demand can translate into sustained instrument and consumables revenue.
10x Genomics (NASDAQ:TXG) set a new 52-week high today, $91.99, as have a number of other biotechs, including, Moderna (NASDAQ:MRNA), $208.90, AbCellera Biologics (NASDAQ:ABCL), $14.90, Viatris (NASDAQ:VTRS), $18.43, and Twist Bioscience (NASDAQ:TWST), $190.76.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
